Integra Lifesciences (NASDAQ:IART) had its target price cut by investment analysts at Wells Fargo & Co from $61.00 to $55.00 in a research note issued to investors on Thursday. The brokerage presently has a “market perform” rating on the life sciences company’s stock. Wells Fargo & Co’s price objective indicates a potential upside of 2.50% from the company’s current price.
A number of other equities research analysts also recently weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $69.00 price target on shares of Integra Lifesciences in a research report on Wednesday, September 12th. Zacks Investment Research downgraded shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 25th. BidaskClub upgraded shares of Integra Lifesciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Bank of America downgraded shares of Integra Lifesciences from a “neutral” rating to an “underperform” rating in a research report on Tuesday, August 7th. They noted that the move was a valuation call. Finally, Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a research report on Friday, August 17th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $61.00.
Shares of NASDAQ IART traded down $0.79 during midday trading on Thursday, reaching $53.66. The company’s stock had a trading volume of 859,674 shares, compared to its average volume of 656,786. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10. Integra Lifesciences has a fifty-two week low of $45.96 and a fifty-two week high of $67.50. The company has a market cap of $4.57 billion, a price-to-earnings ratio of 22.27, a PEG ratio of 1.66 and a beta of 0.76.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.59. Integra Lifesciences had a net margin of 5.49% and a return on equity of 18.01%. The company had revenue of $365.85 million during the quarter, compared to the consensus estimate of $367.89 million. During the same period in the previous year, the business earned $0.45 earnings per share. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. On average, equities research analysts forecast that Integra Lifesciences will post 2.39 earnings per share for the current year.
In related news, insider Jeffrey Mosebrook sold 1,000 shares of the business’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $62.42, for a total value of $62,420.00. Following the sale, the insider now owns 3,085 shares of the company’s stock, valued at $192,565.70. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Glenn Coleman sold 8,916 shares of the business’s stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $63.00, for a total transaction of $561,708.00. Following the completion of the sale, the vice president now directly owns 16,795 shares in the company, valued at approximately $1,058,085. The disclosure for this sale can be found here. Insiders have sold 56,592 shares of company stock valued at $3,573,584 over the last quarter. Company insiders own 5.10% of the company’s stock.
Several institutional investors have recently modified their holdings of IART. Zeke Capital Advisors LLC bought a new stake in shares of Integra Lifesciences in the second quarter worth $204,000. We Are One Seven LLC bought a new stake in Integra Lifesciences during the third quarter valued at $211,000. Eagle Boston Investment Management Inc. acquired a new position in shares of Integra Lifesciences during the second quarter valued at about $223,000. World Asset Management Inc acquired a new position in shares of Integra Lifesciences during the second quarter valued at about $261,000. Finally, Zions Bancorporation acquired a new position in shares of Integra Lifesciences during the third quarter valued at about $272,000. 84.33% of the stock is currently owned by institutional investors.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.